Denali Therapeutics Management
Management criteria checks 4/4
Denali Therapeutics' CEO is Ryan Watts, appointed in Aug 2015, has a tenure of 10.42 years. total yearly compensation is $6.56M, comprised of 10.5% salary and 89.5% bonuses, including company stock and options. directly owns 1.43% of the company’s shares, worth $35.69M. The average tenure of the management team and the board of directors is 7 years and 6.8 years respectively.
Key information
Ryan Watts
Chief executive officer
US$6.6m
Total compensation
| CEO salary percentage | 10.52% |
| CEO tenure | 10.4yrs |
| CEO ownership | 1.4% |
| Management average tenure | 7yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment
Dec 10We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
May 08
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
Mar 20Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Jan 09We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
Dec 09Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Aug 20Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Jul 26Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
May 23Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
May 13An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Apr 17Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Mar 21Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Mar 07Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Feb 21Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Jan 26We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Nov 20Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking
Oct 09Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Aug 22Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price
May 02Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be
Mar 04Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation
Feb 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$499m |
| Jun 30 2025 | n/a | n/a | -US$479m |
| Mar 31 2025 | n/a | n/a | -US$454m |
| Dec 31 2024 | US$7m | US$690k | -US$423m |
| Sep 30 2024 | n/a | n/a | -US$427m |
| Jun 30 2024 | n/a | n/a | -US$420m |
| Mar 31 2024 | n/a | n/a | -US$137m |
| Dec 31 2023 | US$8m | US$670k | -US$145m |
| Sep 30 2023 | n/a | n/a | -US$124m |
| Jun 30 2023 | n/a | n/a | -US$128m |
| Mar 31 2023 | n/a | n/a | -US$371m |
| Dec 31 2022 | US$9m | US$645k | -US$326m |
| Sep 30 2022 | n/a | n/a | -US$303m |
| Jun 30 2022 | n/a | n/a | -US$284m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$13m | US$610k | -US$291m |
| Sep 30 2021 | n/a | n/a | US$30m |
| Jun 30 2021 | n/a | n/a | US$56m |
| Mar 31 2021 | n/a | n/a | US$58m |
| Dec 31 2020 | US$9m | US$589k | US$71m |
| Sep 30 2020 | n/a | n/a | -US$228m |
| Jun 30 2020 | n/a | n/a | -US$216m |
| Mar 31 2020 | n/a | n/a | -US$215m |
| Dec 31 2019 | US$5m | US$567k | -US$198m |
Compensation vs Market: Ryan's total compensation ($USD6.56M) is about average for companies of similar size in the US market ($USD6.87M).
Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.
CEO
Ryan Watts (49 yo)
Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.4yrs | US$6.56m | 1.43% $ 35.7m | |
| Co-Founder | 10.8yrs | US$4.02m | 0.41% $ 10.2m | |
| Chief Technical and Manufacturing Officer | 7.4yrs | no data | no data | |
| Chief Scientific Officer | 5.5yrs | no data | no data | |
| General Counsel | 7yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief Commercial Officer | 4.3yrs | no data | no data | |
| Acting Chief Medical Officer & Head of Development | less than a year | no data | no data |
Experienced Management: DNLI's management team is seasoned and experienced (7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.8yrs | US$6.56m | 1.43% $ 35.7m | |
| Independent Director | 10.8yrs | US$384.47k | 0.22% $ 5.6m | |
| Independent Chairperson | less than a year | no data | 0.21% $ 5.2m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 10.8yrs | US$379.47k | 0.043% $ 1.1m | |
| Member of Scientific Advisory Board | 5.2yrs | no data | no data | |
| Independent Director | 7.8yrs | US$389.43k | 0.014% $ 344.5k | |
| Independent Director | 7.2yrs | US$369.47k | 0.013% $ 321.0k | |
| Independent Director | 3.7yrs | US$359.47k | 0.52% $ 12.9m | |
| Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.8yrs | no data | no data | |
| Independent Director | 5yrs | US$374.47k | 0.012% $ 299.2k |
Experienced Board: DNLI's board of directors are considered experienced (6.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 03:05 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Denali Therapeutics Inc. is covered by 30 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Joel Beatty | Baird |
| Charles Moore | Baird |